Head And Neck Cancer

The addition of pembrolizumab to chemoradiotherapy demonstrated a trend toward longer EFS among patients with locally advanced head and neck squamous cell carcinoma, according to data presented at ESMO Congress.

Electronic noses that detect volatile organic compounds in exhaled breath have emerged as potential tools for cancer detection, but more investigation is needed before they can become part of the diagnostic workup, according to researchers.

Despite recommendations in clinical guidelines, a high proportion of patients with advanced cancer do not have appropriate conversations with health care providers about prognosis, treatment options and end-of-life preferences.

Patients with head and neck cancer who consumed a diet high in nutrients found to deter chronic disease had a 93% lower likelihood of death due to any cause during the first 3 years after diagnosis, according to study results.

Individuals who increased alcohol consumption had higher risks for both alcohol-associated and all cancer types, according to results of a Korean population-based cohort study published in JAMA Network Open.

When planning their next steps after a cancer diagnosis, most patients don’t put a trip to the dentist at the top of their to-do list.

Researchers at New York University, Weill Cornell Medicine and New York Genome Center have developed and tested a two-step approach that uses whole-exome sequencing to find genes and pathways that predict response to immunotherapy.

A phase 3 study of monalizumab among patients with squamous cell carcinoma of the head and neck will be discontinued after a futility interim analysis failed to meet a predefined threshold for efficacy, according to a press release.

A pembrolizumab-based regimen failed to significantly extend EFS among patients with unresected locally advanced head and neck squamous cell carcinoma, according to the agent’s manufacturer.

The FDA granted fast track designation to PDS0101 for treatment of certain patients with head and neck cancer.